TMates Review

TMates Inc. operates the technology platform. Florida corporate records identify an active corporation with a current Miami address. The terms say independent treating providers make all medical decisions, while TMates itself does not practice medicine.

The privacy policy refers to TMates Medical Group or a patient's own provider as the covered healthcare entity and describes TMates Inc. as a business associate. An exact organization-name search of the federal NPI registry returned no TMates or TMates Medical Group record. That does not prove the group lacks licensed clinicians, but it means the named clinical entity could not be independently matched from the published name.

The Our Doctors page says every TMates doctor is U.S.-based, board certified, a graduate of a top-fifty medical school, and has an average of more than fifteen years of experience. It does not publish any clinician name, degree, biography, board, license, or state roster. Those statements are treated as provider marketing rather than independently verified network facts.

The care path begins with a short questionnaire. The current intake opens with height and weight, while product pages say a licensed provider reviews health history and determines whether a prescription is appropriate. The terms permit telehealth consultations and follow-up, and the marketing pages also mention regular virtual consultations. The public material does not establish whether every product is handled asynchronously or requires a live visit.

Compounded semaglutide injection is listed at $249 for one month, $650 for three months, $1,050 for six months, or $1,900 for twelve months. Those effective monthly rates are $249, $216.67, $175, and $158.33. Their unweighted plan-level mean is $199.75, displayed as Avg. $200/mo.

Compounded tirzepatide injection is $297 for one month, $800 for three months, $1,299 for six months, or $1,999 for twelve months. The effective rates are $297, $266.67, $216.50, and $166.58, averaging $236.69 and displayed as Avg. $237/mo.

The semaglutide and tirzepatide pages say medication, support, and shipping are included at the same price across listed doses. The pages do not clearly say whether longer-plan totals are charged fully upfront or through a payment plan, so the draft retains every total without labeling the commitment as prepaid. Checkout remains the controlling source for the initial charge and renewal schedule.

Both compounded GLP-1 pages offer an Oral selector. Semaglutide keeps injection dose buttons and injection-oriented text after the toggle. Tirzepatide changes to 0.25 mg and 0.5 mg buttons while retaining injectable tirzepatide explanations. The exact oral dosage form, concentration, ingredients, quantity, and regimen are not reliable enough for separate cards or price comparisons.

TMates also offers $99-per-month prescription-management services for Wegovy and Zepbound. The pages correctly state that an independent clinician may prescribe when appropriate, the prescription goes to the patient's preferred pharmacy, and TMates does not dispense or ship the brand medication. The $99 is not a medication-included price and should never be compared with a full GLP-1 program total.

Phentermine is labeled $149 per month and Clinical Service Only. The page does not disclose tablet strength, quantity, pharmacy price, or treatment duration. It says a licensed provider reviews the intake and a licensed pharmacy fills an approved prescription, but the $149 card is kept outside medication-price comparison because the product cost and supply unit are not public.

Testosterone cypionate plans are $200 for one month, $450 for three months, $700 for six months, or $1,000 for twelve months. Their monthly rates average $137.50, displayed as Avg. $138/mo. TMates says medication, laboratory work, support, and shipping are included. It describes intramuscular injection and continuing laboratory monitoring, while the actual prescription and dose depend on clinical review.

NAD+ injection uses the same $149, $400, $650, and $1,050 term totals for one, three, six, and twelve months. The effective rates average $119.54, shown as Avg. $120/mo. The page identifies a 1,000 mg per 5 mL vial at 200 mg per mL for subcutaneous use but does not publish a standard patient dose. Its nasal selector describes a 300 mg per mL, 10 mL bottle and two to four sprays daily, yet retains injection side-effect and administration copy, so the nasal variant remains editorial-only.

Sermorelin injection costs $179 for one month, $500 for three months, $900 for six months, or $1,550 for twelve months. The four rates average $156.21, shown as Avg. $156/mo. Medication, support, and shipping are advertised as included, but public strength, vial quantity, dose, laboratory requirements, and monitoring cadence are not listed.

The sexual-health product is a compounded oral tablet containing sildenafil and tadalafil. TMates shows $48 for selectors labeled one dose and six doses without publishing strengths or explaining why both selectors have the same price. Because the exact formula, quantity, and refill cadence are unclear, the combination remains one editorial-only card and is not reduced to either sildenafil or tadalafil alone.

Topical minoxidil foam is offered in 2 percent and 5 percent strengths at $80 per month, with medication, review, support, and shipping described as included. The current reusable AllyRx minoxidil record is oral, so the topical route stays outside direct medication comparison. Hydroquinone 5 percent cream is $40 per order, but the page does not publish the container quantity or refill cadence.

TMates does not name the dispensing pharmacy on the reviewed pages. Its footer says TMates is not a 503A or 503B compounding facility and that actual medication may differ from illustrations. The About page separately calls the company an online pharmacy and manufacturer. Those descriptions do not establish who compounds or dispenses an individual prescription.

Compounded drugs are not FDA approved, and FDA does not verify their safety, effectiveness, or quality before marketing. FDA also states that semaglutide and tirzepatide are not currently on the drug-shortage list or the 503B bulks list. Current law restricts routine copies of commercially available products, while a documented patient-specific significant difference may matter under section 503A. TMates does not publish the assigned pharmacy or patient-specific compounding basis, so the draft does not claim that any prescription is categorically lawful or unlawful.

The product FAQ says TMates generally accepts most major insurance, but the homepage says no insurance is required, several product pages promise no confusing insurance steps, and the terms make the patient responsible when coverage or reimbursement is denied. No clear public HSA or FSA statement was found. Patients should treat the displayed prices as cash-pay amounts unless checkout and the insurer confirm otherwise.

The checkout agreement describes an automatically renewing thirty-day subscription, monthly charges, shipment up to two days early, free shipping, no P.O. boxes, and cancellation at least two days before the next processing date through the portal, phone, or email. It promises a refund after medical disqualification. The formal terms offer a full refund before review or when a patient does not qualify for any medication-assisted weight-loss plan, then no refund after qualification and prescription transmission. The terms do not explain the same outcome as clearly for non-weight-loss products.

Support is available through support@tmates.com, (833) 359-8332, and the patient portal. The contact page says Monday through Friday from 9 a.m. to 6 p.m. Eastern and promises a response within twenty-four hours. The checkout page says specialists are available from 8 a.m. to 8 p.m. Eastern. The broader homepage claim of twenty-four-hour doctor access is not a reliable substitute for defined support or clinician-response hours.

The privacy policy says the audio portion of medical telehealth visits may be recorded, except behavioral-health visits. It also says recordings may be converted to text, machine learning may be performed on received data, Google Analytics and Facebook Pixel are used, and de-identified information may be used without restriction. These disclosures are material for a patient deciding whether to use the platform.